



## ADULT MEDICATION GUIDELINE

# ZIDOVUDINE

<b>Scope (Staff):</b>	All WNHS Staff
<b>Scope (Area):</b>	Obstetrics and Gynaecology

This document should be read in conjunction with the [Disclaimer](#).

### Quick Links

[Dose](#)

[Administration](#)

[Monitoring](#)

[Pregnancy and Breastfeeding](#)

### Restrictions

[Formulary: Restricted](#)

[SAS Category A](#) (item requires approval by TGA)

[HIGH RISK Medication](#) 

### Medication Class

Antiviral agent

### Presentation

**Vials:** 200mg/20mL (10mg/mL)

### Storage

Store at room temperature, below 30°C. Protect from light.

Infusion solution: stable for 24 hours below 25 °C or at 2 to 8 °C.

### Dose

#### Prevention of HIV transmission in labour

##### IV infusion:

*Loading dose:* 2mg/kg maternal body weight for one hour then

*Maintenance dose:* 1mg/kg maternal body weight/hour until birth of the baby

Commence treatment FOUR hours prior to anticipated birth and continue the infusion until birth of

---

the neonate and clamping of the umbilical cord.

## Administration

### IV Infusion

**Reconstitution:** Add 1000mg (5 vials of 200mg/20mL) to 900mL of Glucose 5%.

This equates to a total volume of 1000mL of fluid for administration, giving a concentration of 1mg/mL

For Y site compatibilities click [HERE](#)

## Monitoring

Monitor complete blood count

## Pregnancy

**1<sup>st</sup> Trimester:** Considered safe to use

**2<sup>nd</sup> Trimester:** Considered safe to use

**3<sup>rd</sup> Trimester:** Considered safe to use

## Breastfeeding

Breastfeeding is contraindicated due to the risk of postnatal HIV transmission.

Low levels of Zidovudine in breastmilk, trace amounts in infant

## Comments

The rubber stopper of the vial contains latex and should not be handled by persons who are sensitive or allergic to latex

## Related Policies, Procedures & Guidelines

**HDWA Policies:**

[WA Statewide Medicines Formulary](#)

**WNHS Policy:**

[Antimicrobial Stewardship](#)

**WNHS Clinical Practice Guidelines:**

[HIV Positive: Management of the Woman and her neonate](#)









[High Risk Medicines](#)**KEMH Pharmaceutical & Medicines Management Guidelines:**[Medication Administration](#)**References**

Australian Medicines Handbook. Zidovudine. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2017 [cited 2017 Oct 30]. Available from: <https://amhonline.amh.net.au/>

The Royal Women's Hospital. Zidovudine In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2021 [cited 2021 Dec 22]. Available from: <https://thewomenspbmg.org.au/>

Society of Hospital Pharmacists of Australia. Zidovudine. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2021 [cited 2021 Dec 22]. Available from: <http://aidh.hcn.com.au>

Therapeutic Guidelines. HIV infection in pregnancy. In: eTG complete [Internet]. West Melbourne (Victoria): Therapeutic Guidelines; 2021 [cited 2021 Dec 22]. Available from: <https://tgldcdp.tg.org.au>

Keywords	HIV, human immunodeficiency virus, zidovudine, antiretroviral				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH Pharmacy Department				
Version Info:	4.0				
Date First Issued:	31/07/2015	Last Reviewed:	22/12/2021	Review Date:	22/12/2024
Endorsed by:	Medicines and Therapeutics Committee			Date:	01/03/2022
NSQHS Standards Applicable:	<input checked="" type="checkbox"/>  Std 1: Clinical Governance <input type="checkbox"/>  Std 2: Partnering with Consumers <input checked="" type="checkbox"/>  Std 3: Preventing and Controlling Healthcare Associated Infection <input checked="" type="checkbox"/>  Std 4: Medication Safety		<input type="checkbox"/>  Std 5: Comprehensive Care <input type="checkbox"/>  Std 6: Communicating for Safety <input type="checkbox"/>  Std 7: Blood Management <input type="checkbox"/>  Std 8: Recognising and Responding to Acute Deterioration		
<b>Printed or personally saved electronic copies of this document are considered uncontrolled.          Access the current version from WNHS HealthPoint.</b>					

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2022

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.